What price range applied to Beth Hecht’s Xeris Biopharma (XERS) share sale?

The reported price is a weighted average of $8.0319 per share, with individual sale prices ranging from $7.92 to $8.19. The filing notes the shares were sold in multiple transactions within this band and offers to provide full price breakdowns upon request.

Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an open-market sale of 16,666 shares of common stock at a weighted average price of $8.0319 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.

After this sale, Hecht directly holds 1,161,128 Xeris Biopharma shares, indicating she retains a substantial equity position. Her holdings include 1,288 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, showing ongoing participation in employee ownership programs.

Insider Trade Summary 10b5-1

Net Seller: 16,666 shares ($133,860)

Net Sell 1 txn

Insider Hecht Beth

Role See Remarks

Sold 16,666 shs ($134K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,666	$8.0319	$134K

Holdings After Transaction: Common Stock — 1,161,128 shares (Direct, null)

Footnotes (1)

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 1,288 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.

Key Figures

Shares sold: 16,666 shares Average sale price: $8.0319 per share Post-sale holdings: 1,161,128 shares +2 more

5 metrics

Shares sold 16,666 shares Open-market sale on July 1, 2026

Average sale price $8.0319 per share Weighted average sale price for reported transactions

Post-sale holdings 1,161,128 shares Direct ownership after reported transaction

Recent ESPP acquisition 1,288 shares Acquired on June 30, 2026 under 2018 Employee Stock Purchase Plan

Sale price range $7.92–$8.19 per share Range of individual trade prices within the reported sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Stock Purchase Plan

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Purchase Plan financial

"Includes 1,288 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:39 PM Accepted by SEC EDGAR 07/02/2026 - 04:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last)

(First)

(Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO

ILLINOIS

60607

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		S⁽¹⁾		16,666	D	$8.0319⁽²⁾	1,161,128⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 1,288 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Xeris Biopharma (XERS) report for Beth Hecht?

Beth Hecht reported selling 16,666 shares of Xeris Biopharma common stock in an open-market transaction at a weighted average price of $8.0319 per share. This was disclosed in a Form 4 insider filing with post-transaction direct ownership of 1,161,128 shares.

Was the Xeris Biopharma (XERS) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted by Beth Hecht on August 8, 2025. Such pre-arranged plans allow insiders to schedule trades in advance, helping separate routine portfolio management from discretionary timing decisions.

How many Xeris Biopharma (XERS) shares does Beth Hecht own after the sale?

Following the reported transaction, Beth Hecht directly owns 1,161,128 Xeris Biopharma common shares. This total includes 1,288 shares acquired on June 30, 2026 through the company’s 2018 Employee Stock Purchase Plan, reflecting continued direct equity exposure.

Did Beth Hecht recently acquire Xeris Biopharma (XERS) shares through an employee plan?

Yes. The filing notes that her reported holdings include 1,288 shares acquired on June 30, 2026 under Xeris Biopharma’s 2018 Employee Stock Purchase Plan, as amended. This indicates ongoing participation in the company’s employee share purchase program.